[1]洪 专.精准时代检测先行,生存获益基于 精准的诊断、治疗和预后判断[J].医学信息,2018,(17):1-3.[doi:10.3969/j.issn.1006-1959.2018.17.001]
点击复制

精准时代检测先行,生存获益基于 精准的诊断、治疗和预后判断()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年17期
页码:
1-3
栏目:
肺癌专题
出版日期:
2018-09-01

文章信息/Info

文章编号:
1006-1959(2018)17-0001-03
作者:
洪 专
江苏省肿瘤医院/江苏省肿瘤防治研究所/南京医科大学附属肿瘤医院,江苏 南京 210009
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.17.001
文献标志码:
A

参考文献/References:

[1]Jameson JL,Longo DL.Precision medicine--personalized,problematic,and promising[J].New England Journal of Medicine,2015,372(23):2229-2234. [2]2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More[EB/OL].[2018-03-06].http://www.ascopost.com/News/58902. [3]Precision Medicine[EB/OL].[2018-04-12].https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/precisionmedicine-medicaldevices/default.htm. [4]Daniel Y. Wang,Joe-Elie Salem,Justine V. Cohen,et al.Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors:A Systematic Review and Meta-analysis[J].JAMA Oncol,2018:3923. [5]Gandhi L,Rodríguez-Abreu D,Gadgeel S,et al.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(22):2078-2092. [6]Alice Goodman.KEYNOTE-407:Pembrolizumab Plus Chemotherapy Benefits Response,Survival in Squamous NSCLC[EB/OL].[2018-07-10].http://www.ascopost.com/issues/july-10-2018/keynote-407-pembrolizumab-plus-chemotherapy-in-squamous-nsclc/. [7]Du X,Liu M,Su J,et al.Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice[J].Cell Res,2018,28(4):433-447. [8]Huang Y,Kim BYS,Chan CK,et al.Improving immune-vascular crosstalk for cancer immunotherapy[J].Nat Rev Immunol,2018,18(3):195-203.

更新日期/Last Update: 2018-09-01